Lancet Gastroenterology & Hepatology

Article	Citations
Double Duty	1184
Correction to Lancet Gastroenterol Hepatol 2022; 7: 152–60	416
ESWL pancreatitis: yet another post-procedural pancreatitis to worry about?	403
Stringent criteria for withdrawal of biologics in ulcerative colitis – Authors' reply	397
Improving liver cancer care across Europe	370
Interim evaluation of the colorectal cancer screening programme in the Netherlands	359
Trends in alcohol-specific deaths in the UK and industry responses	332
Global burden of occult hepatitis B virus infection: where we are and what to do	314
Procalcitonin-guided reduction of antibiotic use in acute pancreatitis	302
Comparison of trends in early-onset colorectal cancer in North America and Europe – Authors' reply	280
Comparison of trends in early-onset colorectal cancer in North America and Europe	238
Standardising early liver transplantation for severe alcohol-related hepatitis – Authors' reply	237
Disparities in gastroenterology grand rounds speakerships in the USA	230
USPSTF: colorectal cancer screening in the US from 45 years	225
Challenging stigma around alcohol misuse	194
Research in Brief	193
Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review	190
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial	185
Correction to Lancet Gastroenterol Hepatol 2021; 6: 875	184
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study	181
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled	174
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium	173
Outcomes of minimum unit pricing for alcohol in Scotland	172
Virtual ESMO World Congress on Gastrointestinal Cancer 2021	172
A personalised taper-to-target strategy with adalimumab in Crohn's disease	169

Immune checkpoint inhibitors in colorectal cancer: dream and reality	164
Viral hepatitis in Asia-Pacific: a post-COVID-19 reset	160
Research in Brief	156
The quest for the ideal NASH biomarker	155
Predicting clinical outcomes in people with NAFLD: no need for a crystal ball?	143
Correction to Lancet Gastroenterol Hepatol 2021; 6: 933–46	136
Alcohol-related harms and the case for minimum unit pricing	128
Flux Gourmet: a visual feast with a starved social mission	124
Vedolizumab in paediatric IBD: a huge step forward but not there yet	124
Séverine Vermeire: advancing patient-centred research in IBD	123
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia – Authors' reply	121
Living	121
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection	119
Uncoupler therapy for NAFLD: is flushing a possible harbinger of a safety concern?	111
Ingestion of high-power magnets: cause for concern	108
Correction to Lancet Gastroenterol Hepatol 2021; 6: 569–77	107
Launch of the UN Group of Friends to eliminate hepatitis	106
Research in Brief	104
The Liver Meeting 2023	100
Endoscopic screening for oesophageal cancer: empowering artificial intelligence with a high-quality examination	98
Research in Brief	96
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated rand	94
New WHO guidance for country validation of viral hepatitis B and C elimination	93
A whole-food exclusion diet as monotherapy for Crohn's disease	93
Research in Brief	91
The HEPSANET score to assess treatment eligibility of chronic hepatitis B in Africa	90
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial	90
Reducing disparities in training in inflammatory bowel disease	90
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply	89
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia: 5-year follow-up of a randomised controlled trial	89
Ranking treatments in the network meta-analysis should consider the certainty of evidence – Authors' reply	86
Oral faecal microbiota transplantation in ulcerative colitis – Authors' reply	85
The Other Dark Matter	85
Research in Brief	84
Can genetically engineered pig livers offer patients precious time?	84
Oral faecal microbiota transplantation in ulcerative colitis	82
Gavi's green light for hepatitis B birth dose vaccination in Africa	82
Time to scale up testing and treatment for HBV and HCV in the WHO Eastern Mediterranean Region	81
Simplifying the path to elimination of hepatitis C	80
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship	79
ECCO'24	79
Haematopoietic stem-cell transplantation in Crohn's disease	78
Crunching the numbers for viral hepatitis	77
17th Congress of ECCO	77
Global differences in the management of alcohol-associated hepatitis	74
Treatment withdrawal in Crohn's disease: slowly becoming clearer	74
Giada Sebastiani: a leading voice on liver fibrosis	73
Mystery outbreak of severe acute hepatitis in children	72
Seeing C diff differently	72
Computer-aided detection in real-world colonoscopy: enhancing detection or offering false hope?	71

Robotic pancreatoduodenectomy: preparing for the future	70
Enterobius vermicularis infection associated with positive faecal occult blood testing and eosinophilia	67
Top 10 research priorities for irritable bowel syndrome: results of a James Lind Alliance priority setting partnership	67
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension	66
Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial	66
Augmenting colonoscopy with AI: insights and future directions	66
Research in Brief	65
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, r	65
Ensuring patients with malignant bowel obstruction are central in research and clinical decisions	64
How can I improve my gut health if I am on a special diet?	64
Rusfertide for iron overload in haemochromatosis	64
Spleen stiffness to identify clinically significant portal hypertension	64
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes	63
Hypovolaemic phlebotomy to reduce the need for perioperative transfusion: a price worth paying?	61
The urgent need to end hepatitis B stigma and discrimination	60
Correction to Lancet Gastroenterol Hepatol 2023; 8: 976–89	59
Vedolizumab for prevention of recurrence of Crohn's disease	59
Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy	58
Promoting equity in inflammatory bowel disease: a global approach to care	58
Affordable treatment and political commitment are crucial to eliminate hepatitis C globally	56
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design	56
Infliximab discontinuation in patients with ulcerative colitis	56
The changing prevalence of functional constipation: why words matter	55
Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy	54
Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance	53
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis	53
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroentero	53
Features of gastrointestinal amyloidosis – Authors’ reply	53
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial	53
Treatment de-escalation in Crohn's disease – Author's reply	53
Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease	52
Reset after RESET: insights from a negative trial in coeliac disease	52
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection – Authors' reply	51
Universal hepatitis C virus screening and treatment as part of prenatal care	51
Antimicrobial susceptibility testing for Helicobacter pylori comes of age	50
A new chapter in the campaign to eliminate viral hepatitis?	50
Psychological therapies in inflammatory bowel disease	49
A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia	49
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership	48
Less is more: rethinking colorectal cancer resection strategies in Lynch syndrome	48
Efruxifermin in non-alcoholic steatohepatitis	48
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial	47
High 10-year mortality in alcohol-related liver disease: where do we go from here?	47
Local ablation in pancreatic cancer: some answers and more questions	47
The effect of expectancy versus actual gluten intake on gastrointestinal and extra-intestinal symptoms in non-coeliac gluten sensitivity: a randomised, double-blind, placebo-controlled, international,	47
Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a mult	46
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement	46
Warburg: father of the metabolic approach to cancer	46
LGBTQIA+ affirming palliative care and communication in liver transplantation	46
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma	46
Software-based quantitative assessment of ablation margins: a new standard for liver tumour ablation	45
No accident: the UK infected blood scandal	45
GORD: pain, PPIs, and preciseness	44
Immunotherapy in biliary tract cancer: are we finally on the right path?	44
The case for reducing the use of diagnostic upper and lower gastrointestinal endoscopy	42
EASL Congress 2024	42
Prevention of post-ERCP pancreatitis: the search continues	41
Hepatitis C epidemic among Rohingya refugees in Cox's Bazar: a public health emergency	41
The management of hepatocellular carcinoma	41
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial	41
Intrahepatic cholestasis of pregnancy: are we expecting too much from ursodeoxycholic acid?	40
Chronic Boom	40
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial	40
Inflammatory bowel disease health care for LGTBQIA+ patients	40
Bridging the gap to achieve viral hepatitis mortality targets	39
Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma	39
Lucky: Learning to Live Again	39
Gastric examination by guided capsule endoscopy: a new era	39
The surety or otherwise of leaving chronic hepatitis B untreated	39
Expanding community engagement and advocacy in chronic viral hepatitis	39
The impact of COVID-19 on hepatitis services and civil society organisations	39
Tackling obesity: drugs are only part of the solution	39
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicent	38
Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America	38
Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium	37
Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial	37
Correction to Lancet Gastroenterol Hepatol 2023; 8: 1005–14	35
Correction to Lancet Gastroenterol Hepatol 2022; 7: 736–46	35
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11	35
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial	34

Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease	34
Regional disparities of infections in cirrhosis: a call for action	34
Correction to Lancet Gastroenterol Hepatol 2022; 7: 617–26	34
Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium	34
Viral hepatitis: time for action	33
The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis	33
Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection	33
Integration of public health measures for NAFLD into India's national programme for NCDs	32
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial	32
A call for advocacy and patient voice to eliminate hepatitis B virus infection	31
Covered versus bare-metal stenting in chronic mesenteric ischaemia – Authors' reply	31
Lessons from a trial of colesevelam for bile acid diarrhoea	31
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based th	30
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial	29
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial	29
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial	29
Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic	29
Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial	28
Controversy over colonoscopy for colorectal cancer screening	28
Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models	28
Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials	27
Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study	27
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas	27
Trends and levels of the global, regional, and national burden of appendicitis between 1990 and 2021: findings from the Global Burden of Disease Study 2021	27
Global multi-stakeholder endorsement of the MAFLD definition	27
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives	26
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t	26
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial	26
Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial	25
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial	25
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study	25
International consensus statement on microbiome testing in clinical practice	25
Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial	24
Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual	24
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study	24
Transmural healing as a therapeutic goal in Crohn's disease: a systematic review	23
Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial	23
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement	23
Terlipressin for hepatorenal syndrome: opportunities and challenges	23
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study	23
Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial	22
Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa	22
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial	22
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study	22
Ultra-processed foods and human health: from epidemiological evidence to mechanistic insights	21
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease – Authors’ reply	21
Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis	21
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study	20
Hepatitis C incidence targets among people who inject drugs: a long road ahead	20
The Invisible Extinction	20
Acute kidney injury in liver cirrhosis: a global challenge	20
Idiopathic gastroparesis consensus misses the patient's voice	20
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study	20
Research in Brief	19
Monitoring and treatment of Wilson disease: progress and challenges	19
Digestive Disease Week 2023	19
Ramucirumab plus paclitaxel for gastric cancer in China	19
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease	19
Inflammatory bowel disease in Lebanon: a plea for help	19
Let's talk toilets	18
Research in Brief	18
Endoscopic features of gastrointestinal amyloid light-chain amyloidosis	18
Gastrointestinal services in India during COVID-19: does governance matter?	18
Liver disease admissions in the UK are increasing, urgently needing local and national solutions	18
The status quo of gastroenterology training in the UK	17
Hepatitis C in pregnancy and the TiP-HepC registry	17
Improving equity and access to bariatric surgery	17
Impairment of colorectal cancer screening during the COVID-19 pandemic	17
Towards health equity: the urgent need for upstream intervention studies in gastroenterology and hepatology	17
Charting the path forward to combat gastrointestinal cancers	16
Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study	16
Radical surgery versus organ preservation for early-stage rectal cancer – Authors' reply	16
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada	16
Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA	16
Stent insertion for incurable oesophageal carcinoma: what is the optimal treatment? – Authors' reply	16
Anal cancer screening in low-income and middle-income countries	16
Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study	15
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary?	15
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial	15
The need for affordable, pragmatic, investigator-led clinical trials of treatment strategies in inflammatory bowel disease	15
Research in Brief	15
Expression of concern—Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre random	14
Food insecurity in the UK: a public health issue left to fester	14
Rare cause of dysphagia in a young woman	14
Correction to Lancet Gastroenterol Hepatol 2022; 7: 747–54	14
Poor Little Sick Girls: A Love Letter to Unacceptable Women	14
Research in brief	14
Let this radicalise you	14
Bringing organ preservation closer for selected patients with rectal cancer	14
Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework	14
16th Congress of the European Crohn's and Colitis Organisation	14
COVID-19: Colorectal cancer endoscopic surveillance in IBD	14
The need for a reliable non-invasive diagnostic biomarker for eosinophilic oesophagitis	14
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer	14
Distilling the message: Irish plans for alcohol warning labels	14